Stomach Cancer Global Market Report 2025

Description

Stomach cancer, also known as gastric cancer, is a disease characterized by the formation of malignant (cancerous) cells in the lining of the stomach. It originates in the mucus-producing cells of the stomach's inner layer and can spread to deeper layers and other parts of the body. Stomach cancer typically develops slowly and often shows no symptoms in its early stages, but as it progresses, symptoms such as indigestion, stomach pain, nausea, weight loss, and loss of appetite may occur.

The primary types of stomach cancer include adenocarcinoma, lymphoma, gastrointestinal stromal tumor, carcinoid tumor, and other variants. Adenocarcinoma is a type of cancer that develops in the glandular cells lining certain internal organs and is commonly found in the stomach, lungs, prostate, and colon. Treatment options encompass chemotherapy, targeted therapy, immunotherapy, radiation therapy, and surgical procedures, administered via various routes such as oral and parenteral. Distribution occurs through multiple channels, including hospital pharmacies, retail pharmacies, and online pharmacies, serving a range of end users like hospitals, specialty clinics, ambulatory surgery centers, and others.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the consequent trade frictions in spring 2025 are severely impacting the healthcare sector, particularly in the supply of critical medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are facing higher costs for imported surgical instruments, imaging equipment, and consumables such as syringes and catheters, many of which have limited domestic alternatives. These increased costs are straining healthcare budgets, leading some providers to delay equipment upgrades or pass on expenses to patients. Additionally, tariffs on raw materials and components are disrupting the production of essential drugs and devices, causing supply chain bottlenecks. In response, the industry is diversifying sourcing strategies, boosting local manufacturing where possible, and advocating for tariff exemptions on life-saving medical products.

The stomach cancer market research report is one of a series of new reports from The Business Research Company that provides stomach cancer market statistics, including stomach cancer global market size, regional shares, competitors with stomach cancer market share, detailed stomach cancer market segments, market trends and opportunities, and any further data you may need to thrive in the stomach cancer industry. The stomach cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The stomach cancer market size has grown rapidly in recent years. It will grow from $3.27 billion in 2024 to $3.74 billion in 2025 at a compound annual growth rate (CAGR) of 14.1%. The growth observed during the historic period can be attributed to the increasing prevalence of Helicobacter pylori infection, advancements in targeted therapy development, greater use of combination chemotherapy regimens, rising availability of immunotherapy treatments, and shifting lifestyle patterns.

The stomach cancer market size is expected to see rapid growth in the next few years. It will grow to $6.28 billion in 2029 at a compound annual growth rate (CAGR) of 13.9%. The growth during the forecast period can be attributed to a rise in global stomach cancer incidence rates, increased public and private healthcare spending, a surge in approvals of targeted therapies and biologics, growing interest from pharmaceutical companies in oncology, and an increase in collaborations between research institutions and biotech firms. Major trends expected in this period include the integration of companion diagnostics, incorporation of genomic testing in clinical practice, innovations in immunotherapy combinations, advancements in endoscopic techniques, and the development of microbiome-based therapies.

The increasing prevalence of Helicobacter pylori infection is anticipated to drive the growth of the stomach cancer market in the coming years. Helicobacter pylori infection occurs when the bacteria Helicobacter pylori colonize the stomach lining, causing inflammation, ulcers, and elevating the risk of stomach cancer. This rise in infection rates is mainly attributed to poor sanitation, which promotes fecal-oral and oral-oral transmission of the bacteria in overcrowded or unsanitary living environments. Helicobacter pylori contributes to stomach cancer by inducing chronic inflammation and cellular damage in the stomach lining, leading to precancerous changes and tumor formation. For example, in November 2024, the Government of Canada reported that the recurrence rate of Helicobacter pylori infection was 19% in 2023, with variations depending on geographic location and age. Thus, the growing prevalence of Helicobacter pylori infection is fueling the expansion of the stomach cancer market.

Key players in the stomach cancer treatment market are focusing on developing advanced therapies such as claudin (CLDN18.2)-targeted cytolytic antibody therapy to improve first-line treatment for HER2-negative gastric and gastroesophageal junction (GEJ) adenocarcinoma. This therapy uses a monoclonal antibody designed to specifically bind to tumor cells expressing CLDN18.2 and trigger cytotoxic effects when combined with chemotherapy, enhancing both progression-free and overall survival rates. For instance, in October 2024, Astellas Pharma US, Inc., a Japan-based pharmaceutical firm, introduced Vyloy (zolbetuximab-clzb), a claudin (CLDN18.2)-targeted cytolytic antibody for treating gastric and GEJ cancers. Administered intravenously alongside fluoropyrimidine- and platinum-based chemotherapy, this innovative biologic demonstrated median progression-free survival of up to 10.6 months and overall survival of up to 18.2 months in clinical trials. By selectively targeting CLDN18.2-positive cancer cells, it reduces off-target toxicity and enhances treatment specificity, representing a major advancement in personalized oncology for advanced gastric cancer.

In February 2025, GSK plc., a UK-based pharmaceutical company, acquired IDRx, Inc. for $1.15 billion. With this acquisition, GSK aims to bolster its oncology pipeline by advancing innovative targeted therapies for cancer treatment. IDRx, Inc., a US-based biopharmaceutical company, specializes in the discovery and development of precision oncology treatments that target specific genetic mutations in cancer.

Major players in the stomach cancer market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck And Co. Inc., Sanofi S.A., Bristol Myers Squibb Company, AstraZeneca plc, Novartis Ag, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited., Eli Lilly And Company, Amgen Inc, Mayo Clinic, Daiichi Sankyo Company Limited., Illumina Inc., BeiGene Ltd., Celltrion Healthcare Co. Ltd., Biocon Limited., Guardant Health Inc., Zai Lab Limited., MacroGenics Inc.

North America was the largest region in the stomach cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in stomach cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the stomach cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The stomach cancer market consists of revenues earned by entities by providing services such as diagnostic services, surgical services, post-treatment monitoring and palliative care, genetic and biomarker testing, and clinical trial services. The market value includes the value of related goods sold by the service provider or included within the service offering. The stomach cancer market also includes sales of diagnostic tools and kits, surgical instruments and devices, companion diagnostics, supportive care medications, and biomarker testing kits. Values in this market are 'factory gate' values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Stomach Cancer Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on stomach cancer market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for stomach cancer ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The stomach cancer market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Type: Adenocarcinoma; Lymphoma; Gastrointestinal Stromal Tumor; Carcinoid Tumor; Other Types
2) By Therapy Type: Chemotherapy; Targeted Therapy; Immunotherapy; Radiation Therapy; Surgery
3) By Route of Administration: Oral; Parenteral
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
5) By End-User: Ambulatory Surgery Centers; Hospitals And Specialty Clinics; Other End-Users
Subsegments:
1) By Adenocarcinoma: Intestinal Type; Diffuse Type
2) By Lymphoma: Mucosa-Associated Lymphoid Tissue Lymphoma; Diffuse Large B-Cell Lymphoma
3) By Gastrointestinal Stromal Tumor: Kit-Positive Gastrointestinal Stromal Tumor; Platelet-Derived Growth Factor Receptor Alpha-mutant Gastrointestinal Stromal; Wild-Type Gastrointestinal Stromal Tumors
4) By Carcinoid Tumor: Typical Carcinoid; Atypical Carcinoid
5) By Other Types: Squamous Cell Carcinoma; Small Cell Carcinoma; Undifferentiated Tumors
Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd; Merck And Co. Inc.; Sanofi S.A.; Bristol Myers Squibb Company; AstraZeneca plc; Novartis Ag; GlaxoSmithKline plc; Takeda Pharmaceutical Company Limited.; Eli Lilly And Company; Amgen Inc; Mayo Clinic; Daiichi Sankyo Company Limited.; Illumina Inc.; BeiGene Ltd.; Celltrion Healthcare Co. Ltd.; Biocon Limited.; Guardant Health Inc.; Zai Lab Limited.; MacroGenics Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r37142

1. Executive Summary

2. Stomach Cancer Market Characteristics

3. Stomach Cancer Market Trends And Strategies

4. Stomach Cancer Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Stomach Cancer Growth Analysis And Strategic Analysis Framework

5.1. Global Stomach Cancer PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Stomach Cancer Market Growth Rate Analysis
5.4. Global Stomach Cancer Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Stomach Cancer Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Stomach Cancer Total Addressable Market (TAM)

6. Stomach Cancer Market Segmentation

6.1. Global Stomach Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Adenocarcinoma
Lymphoma
Gastrointestinal Stromal Tumor
Carcinoid Tumor
Other Types
6.2. Global Stomach Cancer Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Chemotherapy
Targeted Therapy
Immunotherapy
Radiation Therapy
Surgery
6.3. Global Stomach Cancer Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Oral
Parenteral
6.4. Global Stomach Cancer Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
6.5. Global Stomach Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Ambulatory Surgery Centers
Hospitals And Specialty Clinics
Other End-Users
6.6. Global Stomach Cancer Market, Sub-Segmentation Of Adenocarcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Intestinal Type
Diffuse Type
6.7. Global Stomach Cancer Market, Sub-Segmentation Of Lymphoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Mucosa-Associated Lymphoid Tissue Lymphoma
Diffuse Large B-Cell Lymphoma
6.8. Global Stomach Cancer Market, Sub-Segmentation Of Gastrointestinal Stromal Tumor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Kit-Positive Gastrointestinal Stromal Tumor
Platelet-Derived Growth Factor Receptor Alpha-mutant Gastrointestinal Stromal
Wild-Type Gastrointestinal Stromal Tumors
6.9. Global Stomach Cancer Market, Sub-Segmentation Of Carcinoid Tumor, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Typical Carcinoid
Atypical Carcinoid
6.10. Global Stomach Cancer Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Squamous Cell Carcinoma
Small Cell Carcinoma
Undifferentiated Tumors

7. Stomach Cancer Market Regional And Country Analysis

7.1. Global Stomach Cancer Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Stomach Cancer Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Stomach Cancer Market

8.1. Asia-Pacific Stomach Cancer Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Stomach Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Stomach Cancer Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Stomach Cancer Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Stomach Cancer Market

9.1. China Stomach Cancer Market Overview
9.2. China Stomach Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Stomach Cancer Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Stomach Cancer Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Stomach Cancer Market

10.1. India Stomach Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Stomach Cancer Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Stomach Cancer Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Stomach Cancer Market

11.1. Japan Stomach Cancer Market Overview
11.2. Japan Stomach Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Stomach Cancer Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Stomach Cancer Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Stomach Cancer Market

12.1. Australia Stomach Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Stomach Cancer Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Stomach Cancer Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Stomach Cancer Market

13.1. Indonesia Stomach Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Stomach Cancer Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Stomach Cancer Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Stomach Cancer Market

14.1. South Korea Stomach Cancer Market Overview
14.2. South Korea Stomach Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Stomach Cancer Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Stomach Cancer Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Stomach Cancer Market

15.1. Western Europe Stomach Cancer Market Overview
15.2. Western Europe Stomach Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Stomach Cancer Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Stomach Cancer Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Stomach Cancer Market

16.1. UK Stomach Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Stomach Cancer Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Stomach Cancer Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Stomach Cancer Market

17.1. Germany Stomach Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Stomach Cancer Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Stomach Cancer Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Stomach Cancer Market

18.1. France Stomach Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Stomach Cancer Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Stomach Cancer Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Stomach Cancer Market

19.1. Italy Stomach Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Stomach Cancer Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Stomach Cancer Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Stomach Cancer Market

20.1. Spain Stomach Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Stomach Cancer Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Stomach Cancer Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Stomach Cancer Market

21.1. Eastern Europe Stomach Cancer Market Overview
21.2. Eastern Europe Stomach Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Stomach Cancer Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Stomach Cancer Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Stomach Cancer Market

22.1. Russia Stomach Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Stomach Cancer Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Stomach Cancer Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Stomach Cancer Market

23.1. North America Stomach Cancer Market Overview
23.2. North America Stomach Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Stomach Cancer Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Stomach Cancer Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Stomach Cancer Market

24.1. USA Stomach Cancer Market Overview
24.2. USA Stomach Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Stomach Cancer Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Stomach Cancer Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Stomach Cancer Market

25.1. Canada Stomach Cancer Market Overview
25.2. Canada Stomach Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Stomach Cancer Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Stomach Cancer Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Stomach Cancer Market

26.1. South America Stomach Cancer Market Overview
26.2. South America Stomach Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Stomach Cancer Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Stomach Cancer Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Stomach Cancer Market

27.1. Brazil Stomach Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Stomach Cancer Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Stomach Cancer Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Stomach Cancer Market

28.1. Middle East Stomach Cancer Market Overview
28.2. Middle East Stomach Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Stomach Cancer Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Stomach Cancer Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Stomach Cancer Market

29.1. Africa Stomach Cancer Market Overview
29.2. Africa Stomach Cancer Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Stomach Cancer Market, Segmentation By Therapy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Stomach Cancer Market, Segmentation By Route of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Stomach Cancer Market Competitive Landscape And Company Profiles

30.1. Stomach Cancer Market Competitive Landscape
30.2. Stomach Cancer Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Merck And Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis

31. Stomach Cancer Market Other Major And Innovative Companies

31.1. AstraZeneca plc
31.2. Novartis Ag
31.3. GlaxoSmithKline plc
31.4. Takeda Pharmaceutical Company Limited.
31.5. Eli Lilly And Company
31.6. Amgen Inc
31.7. Mayo Clinic
31.8. Daiichi Sankyo Company Limited.
31.9. Illumina Inc.
31.10. BeiGene Ltd.
31.11. Celltrion Healthcare Co. Ltd.
31.12. Biocon Limited.
31.13. Guardant Health Inc.
31.14. Zai Lab Limited.
31.15. MacroGenics Inc.

32. Global Stomach Cancer Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Stomach Cancer Market

34. Recent Developments In The Stomach Cancer Market

35. Stomach Cancer Market High Potential Countries, Segments and Strategies

35.1 Stomach Cancer Market In 2029 - Countries Offering Most New Opportunities
35.2 Stomach Cancer Market In 2029 - Segments Offering Most New Opportunities
35.3 Stomach Cancer Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer